Latest news with #DavidRegan
The Market Online
08-07-2025
- Business
- The Market Online
Sona Nanotech doses first patient in groundbreaking cancer therapy trial
Sona Nanotech (CSE:SONA) announced that the first patient has been dosed in its early feasibility study of Targeted Hyperthermia Therapy (THT) for advanced melanoma If successful, THT could represent a significant advancement in cancer therapy, particularly for patients who have exhausted existing treatment options The study marks the first human application of Sona's THT, a therapy that utilizes the company's proprietary biocompatible gold nanorod technology Shares of Sona Nanotech (CSE:SONA) last traded at $0.48 Sona Nanotech (CSE:SONA), an oncology-focused life sciences company, has announced a major milestone in the development of its novel cancer treatment: the first patient has been dosed in its early feasibility study of Targeted Hyperthermia Therapy (THT) for advanced melanoma. This content has been prepared in collaboration with Sona Nanotech Inc., a third-party issuer, and is intended for informational purposes only. The study marks the first human application of Sona's THT, a therapy that utilizes the company's proprietary biocompatible gold nanorod (GNR) technology. This innovative approach aims to enhance the immune system's ability to recognize and attack tumors by applying localized hyperthermia to cancer cells, potentially making them more visible to immune responses. Study overview The early feasibility study is designed to evaluate several critical aspects of the THT treatment: Safety and tolerability : Monitoring for adverse events during and after treatment. : Monitoring for adverse events during and after treatment. Preliminary efficacy : Measuring tumor growth inhibition and immune system engagement. : Measuring tumor growth inhibition and immune system engagement. Clinical and pathological response: Assessing changes in tumor size and histological evidence of immune activation. Patients enrolled in the study have advanced melanoma and have either failed to respond to or progressed during standard immunotherapy treatments. Each participant will receive two THT treatments spaced one week apart. Technology and clinical evaluation The study will also assess the practicality of implementing THT in clinical settings, including: Ease of setup and preparation Administration of GNRs across various tumor types Reproducibility and training requirements Resource and time demands for treatment delivery Leadership commentary Dr. Carman Giacomantonio, Sona's chief medical officer, explained that this new therapy aims to modify tumors making them more visible to the immune system with a view to enabling an elimination of the cancer. 'As with any new technology, we are required to demonstrate that we can safely and feasibly deliver the treatment in the clinical setting,' he said in a media release. 'Success in this study will enable us to proceed to our next planned study that will more critically evaluate the biological effects and clinical outcomes of this exciting technology. CEO David Regan added: 'We plan to follow this critical first clinical step quickly with a second, more expansive human trial following further engagement with regulators, as well as a peer-reviewed article in a leading scientific journal detailing our findings. We also expect the learnings from this study to help inform on THT's potential for complementing the treatment of other cancer types.' What's next Initial results from the study are expected later this summer, with final data anticipated in the fall. Sona plans to publish its findings in a peer-reviewed journal and engage with regulators to advance to the next phase of clinical development. If successful, THT could represent a significant advancement in cancer therapy, particularly for patients who have exhausted existing treatment options. About Sona Nanotech Sona Nanotech operates out of Halifax, Nova Scotia and is a company developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. Shares of Sona Nanotech (CSE:SONA) ended Monday 9.43 per cent lower at $0.48 but has risen 84.62 per cent since the year began and is also up 71.43 per cent since this time last year. Join the discussion: Find out what everybody's saying about this stock on the SonaNanotech Bullboard investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
Axios
08-05-2025
- Politics
- Axios
School board races, tax increases are on the ballot
Early voting for next week's election (yes, there's an election) starts Tuesday. 🏫 State of play: A handful of school districts in NWA have school board elections and millage rate increases on the ballot starting today. Election Day is May 13. 💰 Zoom in: If you live in the Farmington, Greenland or Prairie Grove school districts, you have tax increases to consider. The school districts are requesting millage rate increases of: Four mills for a total of 44.1 mills in Farmington. Two mills for a total of 41.1 mills in Greenland. Four mills for a total of 44.6 mills in Prairie Grove. 🏡 How it works: For every one mill increase, you will pay $20 more per year in property taxes per $100,000 that your property is worth. A mill is equal to $1 of property tax for each $1,000 of assessed value. The assessed value of property in Arkansas is 20% of its market value, according to Washington County. 🧑💼 Contested school board races include: Rogers, Zone 5 — Elizabeth-Ann "Liz" Lee vs. David Regan vs. Jessica L. Thompson Springdale, Zone 5 — Incumbent Izmar (Eddie) Ramos vs. Donald C. Tippett Gravette, Zone 2 — Matt Croxdale vs. Dani Madison Greenland, Zone 4 — Kayden Dennis vs. Audrey Filmore Prairie Grove, Position 1 — Incumbent Whitney Woods Bryant vs. Ricky Carte 🚒 Zoom out: Some Benton County voters will also decide whether to increase dues for the Pleasure Heights volunteer fire department from $40 to $100 annually. Gravette voters will see an option to have fire department dues included in property tax bills. This is a change from billing separately in the mail, 5News reported. The dues are $50 annually for improved property and $35 annually for unimproved property.
Globe and Mail
01-05-2025
- Business
- Globe and Mail
Sona Nanotech Announces Annual Options Grants
Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan. Sona CEO, David Regan, commented, " These options include the annual compensation for our directors, who do not receive any cash compensation, and incentive options for our team providing for strong alignment with shareholder's interests. The Company continues to steward investor capital efficiently while making strong progress towards advancing Sona's novel THT cancer treatment towards the clinic. The entire Sona team is engaged and excited as we near the opportunity to showcase THT in a first-in-human clinical trial with initial read-outs expected this summer." About Sona Nanotech Inc. Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
